Cytosorbents Corp (NASDAQ:CTSO) – Equities researchers at B. Riley cut their FY2019 earnings per share (EPS) estimates for shares of Cytosorbents in a report released on Wednesday, November 6th. B. Riley analyst A. D’silva now anticipates that the medical research company will post earnings of ($0.63) per share for the year, down from their previous forecast of ($0.44). B. Riley currently has a “Buy” rating and a $10.00 price target on the stock. B. Riley also issued estimates for Cytosorbents’ Q4 2019 earnings at ($0.15) EPS, Q1 2020 earnings at ($0.14) EPS, Q2 2020 earnings at ($0.12) EPS, Q3 2020 earnings at ($0.13) EPS, Q4 2020 earnings at ($0.09) EPS, FY2020 earnings at ($0.48) EPS, FY2021 earnings at ($0.10) EPS and FY2022 earnings at $0.22 EPS.
Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.49 million. Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 142.91%.
A number of other research firms have also issued reports on CTSO. ValuEngine lowered shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Maxim Group set a $14.00 target price on shares of Cytosorbents and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Cytosorbents in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Cytosorbents has an average rating of “Hold” and a consensus target price of $13.00.
Shares of Cytosorbents stock traded up $0.11 during midday trading on Friday, reaching $4.61. 9,511 shares of the company’s stock traded hands, compared to its average volume of 121,597. The company has a market cap of $163.78 million, a price-to-earnings ratio of -8.25 and a beta of 1.68. The company’s 50 day simple moving average is $4.90 and its 200 day simple moving average is $5.93. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.00 and a current ratio of 3.21. Cytosorbents has a 52 week low of $3.68 and a 52 week high of $11.50.
In other news, CFO Kathleen P. Bloch bought 6,500 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $4.83 per share, for a total transaction of $31,395.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.60% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Sargent Investment Group LLC grew its stake in Cytosorbents by 15.9% in the 2nd quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock valued at $2,207,000 after buying an additional 45,840 shares during the last quarter. Avenir Corp grew its stake in Cytosorbents by 66.6% in the 2nd quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock valued at $960,000 after buying an additional 58,060 shares during the last quarter. Advisor Group Inc. grew its stake in Cytosorbents by 15.8% in the 2nd quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock valued at $219,000 after buying an additional 4,530 shares during the last quarter. Northern Trust Corp grew its stake in Cytosorbents by 1.7% in the 2nd quarter. Northern Trust Corp now owns 354,447 shares of the medical research company’s stock valued at $2,343,000 after buying an additional 5,852 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Cytosorbents by 1.1% in the 2nd quarter. BlackRock Inc. now owns 2,008,123 shares of the medical research company’s stock valued at $13,274,000 after buying an additional 21,791 shares during the last quarter. Institutional investors and hedge funds own 26.45% of the company’s stock.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Read More: Dollar Cost Averaging
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.